In the present study, we investigated the role of nucleotide oligomerization domain-like receptor family pyrin domain containing 6 (NLRP6) in rheumatoid arthritis (RA) and explored the underlying mechanism. We found that both mRNA and protein levels of NLRP6 are attenuated in synovial tissues and fibroblast-like synoviocytes (FLS) of RA patients compared to patients with osteoarthritis. We also observed that pro-inflammatory cytokine production is decreased and nuclear factor-kappa B activation is inhibited in NLRP6-overexpressing RA-FLS. Furthermore, we found that NLRP6 overexpression promotes transforming growth factor-b-activated kinase 1-binding protein 2/3 lysosome-dependent degradation, and we provide evidence showing that NLRP6 plays the role of providing the docking site to facilitate the interaction between transforming growth factor-b-activated kinase 1-binding protein 2/3 and tripartite motif 38 in RA-FLS.
The autoimmune disease rheumatoid arthritis (RA) is a chronic systemic inflammatory disease. It is characterized by persistent synovial inflammation and progressive joint destruction [1] . Fibroblast-like synoviocytes (FLS) could form the synovial intimal lining of diarthrodial joints, they also respond to pro-inflammatory stimuli such as tumor necrosis factor (TNF)-a and interleukin (IL)-1 and exhibit features of inflammatory cells contributing to the pathogenesis of RA [2, 3] . Previous studies have confirmed that FLS play crucial roles in this process by producing cytokines that perpetuate autoimmune inflammation and proteases that contribute to cartilage destruction [4] [5] [6] .
The nucleotide oligomerization domain (NOD)-like receptor (NLR) family proteins are key regulators of immune responses during infection and autoimmunity [7] . NOD-like receptor family pyrin domain containing 6 (NLRP6), which belongs to the NLRP subfamily of NLRs, is highly expressed in the intestine but is reduced in colitis and colorectal cancer, and it has been adequately studied as a negative regulator of intestinal inflammation and tumorigenesis [8] [9] [10] . Recently, many studies have found that NLRs play critical functions in autoimmune diseases [11, 12] , although the role of NLRP6 in RA still remains unknown.
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In the present study, we investigated the function of NLRP6 in RA and revealed a novel underlying mechanism. We found that NLRP6 expression was down-regulated in RA-FLS compared to osteoarthritis (OA)-FLS. Furthermore, we transfected NLRP6 expression plasmid or NLRP6 specific small interfering RNA (siRNA) into RA-FLS to examine the function of NLRP6, and we observed that NLRP6 could inhibit the activation of nuclear factor-kappa B (NF-jB) signaling, as well as suppress the production of proinflammatory cytokines and matrix metalloproteinases (MMPs) in TNF-a-stimulated RA-FLS. Most importantly, we found that NLRP6 overexpression promoted transforming growth factor-b-activated kinase 1 (TAK1)-binding protein 2/3 (TAB2/3) lysosomedependent degradation, and we assumed that NLRP6 may provide the docking site to facilitate the interaction between TAB2/3 and Tripartite motif 38 (TRIM38) in RA-FLS in response to TNF-a. In conclusion, we have revealed an anti-inflammatory role of NLRP6 in RA-FLS, and suggest NLRP6 is a potential therapeutic target for RA.
Materials and methods

Patients, synovial tissues and FLS
Synovial tissues were collected from eight RA patients and eight OA patients from the Department of Orthopedics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. All patients in the present study fulfilled the 1987 revised criteria for the classification of global functional status in RA of the American College of Rheumatology. Informed consent was obtained from all patients and the study protocol was approved by the Ethics Committee of Huazhong University of Science and Technology. FLS were isolated from the synovial tissues by a modified tissue culture method [13] . Cells were cultured at 37°C in a humidified atmosphere containing 5% CO 2 in Dulbecco's modiefied Eagle's medium with 20% fetal bovine serum (Gibco, Gaithersburg, MD, USA), 100 U mL À1 penicillin and 100 mg mL À1 streptomycin. FLS from passages three to five were used in the present study. 
RNA analysis
ELISA
Human IL-6 and IL-1b ELISA kits (R&D Systems, Minneapolis, MN, USA) were used in accordance with the manufacturer's instructions to measure the protein levels of human IL-6 and IL-1b in cell-free FLS supernatants.
Dual-luciferase reporter assay
The experiments were performed as described previously [14] . Luciferase activity of the NF-jB promoter was evaluated using a dual-luciferase reporter assay system (Promega) and detected with a spectraMax M5 reader (Molecular Devices, Sunnyvale, CA, USA).
Western blot analysis and immunoprecipitation
The synovial tissues and FLS were lysed using RIPA buffer (MDL Biotechnology) and total protein in the supernatants was quantified using a BCA protein assay kit (Thermo Scientific, Waltham, MA, USA). Immunoprecipitation and western blot analysis were performed as described previously [15] . The antibodies for NLRP6 (#ab116007), TAB2 (#ab172412), TAB3 (#ab85655), TRIM38 (#ab156789) and TRAF2 (#ab37119) were obtained from Abcam (Cambridge, MA, USA); those for p65 (#8242), p-p65 (#3033), IjBa (#4814) and p-IjBa (#2859) were obtained from Cell Signaling Technology (Beverly, MA, USA); and those for RNF4 (#sc-21351), TAK1 (#sc-7967) and GAPDH (sc-51907) were obtained from Santa Cruz Biotechnology.
Statistical analysis
All data are presented as the mean AE SD of three experiments. Statistical significance was determined with a twotailed Student's t-test. P < 0.05 was considered statistically significant.
Results
NLRP6 expression was decreased in RA-FLS compared to OA-FLS
To investigate the role of NLRP6 in RA, initially, we examined the expression of NLRP6 in RA. As shown in Fig. 1A , the expression of NLRP6 was significantly decreased in synovial tissues from RA patients both in mRNA and protein levels. Because of the important roles of FLS in the pathogenesis of RA, we investigated the expression of NLRP6 in FLS and, consistent with the results obtained in synovial tissues, we found that mRNA and protein levels of NLRP6 were obviously down-regulated in RA-FLS compared to OA-FLS (Fig. 1B) . Furthermore, we found that the expression of NLRP6 was significantly decreased in response to inflammatory stimuli such as lipopolysaccharide, IL-1b and TNF-a, but not interferon-c (Fig. 1C ). TNF-a is the most common pro-inflammatory stimuli involved in RA pathogenesis, and multiple TNF-a inhibitors have been shown to be effective in the treatment of RA [16, 17] . Accordingly, we mainly used TNF-a as stimulus in the present study and found that NLRP6 expression was decreased in a time-dependent manner in RA-FLS stimulated with TNF-a (Fig. 1D) .
Overexpression of NLRP6 inhibited the inflammatory status in TNF-a treated RA-FLS NLRP6 has been well studied as a negative regulator of intestinal inflammation and tumorigenesis, and so we examined whether NLRP6 could also inhibit the inflammatory status in RA-FLS. We transfected NLRP6 expression plasmid into RA-FLS and the efficiency of overexpression was confirmed ( Fig. 2A) . NLRP6 overexpression significantly suppressed the mRNA level of different types of inflammatory cytokines, such as IL-6, IL-1b and TNF-a, as well as MMPs, such as MMP1 and MMP13, in TNF-a-stimulated RA-FLS (Fig. 2B) . Furthermore, we examined the protein level of these inflammatory mediators in supernatants by ELISA and observed that the secreted protein levels of IL-6 and IL1b were both suppressed in NLRP6 overexpressed RA-FLS after TNFa stimulation (Fig. 2C) .
Knockdown of the expression of NLRP6 aggravated the inflammatory status in TNF-a treated RA-FLS
To better understand the function of NLRP6 in regulating inflammatory status in RA-FLS, synthesized interfering RNA targeting NLRP6 was used to suppress endogenous NLRP6 expression, and the NLRP6 expression was significantly attenuated with transfection of NLRP6 specific siRNA into RA-FLS (Fig. 3A) . Consistent with the overexpression results, we found that silencing of NLRP6 increased the expression of cytokines and MMPs (Fig. 3B ) and protein levels of IL-6 and IL-1b were also enhanced (Fig. 3C) .
NLRP6 suppressed the activation of the NF-jB pathway NF-jB has represented a paradigm for signal transduction and pro-inflammatory cytokines production implicated in numerous diseases, including RA [18, 19] . Accordingly, we aimed to investigate the relationship between NLRP6 and the NF-jB pathway in RA-FLS. Similar to the previous findings obtained in macrophages [9] , we found that NLRP6 overexpression suppressed the phosphorylation of p65 and IjBa, ) for 16 h. **P < 0.01, ***P < 0.001. Data are representative of three independent experiments with similar results (mean AE SD).
indicating the inhibition of NF-jB pathway (Fig. 4A) . In addition, we used a dual-luciferase reporter assay to examine the activation of NF-jB signaling, and found that the activation of NF-jB was also inhibited in NLRP6 overexpressed RA-FLS compared to RA-FLS transfected with empty vector after TNF-a stimulation (Fig. 4B) . Consistent with the overexpression results, in RA-FLS transfected with NLRP6 specific siRNA, the phosphorylation of p65 and IjBa was significantly increased (Fig. 4C ) and the activation of NF-jB signaling was greatly enhanced (Fig. 4D) .
NLRP6 promoted TAB2/3 lysosome-dependent degradation
To further clarify the mechanism by which NLRP6 inhibited the activation of NF-jB signaling, we first examined the expression of diverse proteins in this pathway in NLRP6 overexpressed RA-FLS after TNF-a treatment. Interestingly, we found the expression of TAB2 and TAB3 was down-regulated in RA-FLS transfected with NLRP6 expression plasmid in the presence of TNF-a, although the levels of tumor necrosis factor receptor-associated factor 2 (TRAF2) or TAK1 were not affected (Fig. 5A ). As shown in Fig. 5B , we found that NLRP6 promoted TAB2/3 degradation in a dose-dependent manner. In addition, we found that NLRP6-induced degradation of TAB2/3 could be reversed by lysosome inhibitor chloroquine but not by proteasome inhibitor mg132 (Fig. 5C ).
NLRP6 provided a docking site to facilitate the interaction between TAB2/3 and TRIM38
To investigate why NLRP6 can promote the lysosomedependent degradation of TAB2/3, we hypothesized that NLRP6 might play as a scaffold and provided the docking site to facilitate the interaction between TAB2/3 and other proteins that directly affect the degradation of TAB2/3 through lysosome. Indeed, we found that NLRP6 could interact with TAB2 and TAB3, and the interaction was significantly enhanced after TNF-a stimulation in NLRP6 overexpressed RA-FLS (Fig. 6A ). Most importantly, we found that NLRP6 could interact with TRIM38, which has been shown to interact with TAB2/3 and promote lysosome-dependent degradation of TAB2/3, and the interaction between NLRP6 and TRIM38 was also enhanced after TNF-a stimulation (Fig. 6A) . Another protein RING finger protein 4 (RNF4) which also reported as a facilitator of lysosome-dependent degradation of TAB2/3, was not found to interact with NLRP6 in RA-FLS (Fig. 6A) . Consistent with this result, we found that TAB2/3 and TRIM38 interact with NLRP6 obviously after TNF-a stimulation in RA-FLS transfected with the negative control siRNA, although the interaction was significantly decreased when NLRP6 expression was attenuated by siRNA (Fig. 6B) . These results indicate that NLRP6 may play the role of providing a docking site to facilitate the interaction between TAB2/3 and TRIM38 in RA-FLS with the presence of TNF-a.
Discussion
In the present study, we have demonstrated the decreased expression of NLRP6 in RA-FLS compared to OA-FLS, and we also investigated the role of and IjBa in RA-FLS transfected with negative control siRNA or NLRP6 specific siRNA was examined by western blotting after being stimulated with TNF-a (100 ng mL
À1
) for 16 h. (C) RA-FLS were transfected with EV or NLRP6 expression plasmid together with NF-jB reporter plasmid and phRL-TK plasmid (internal control) for 24 h, followed by the stimulation with TNF-a for 16 h, the activation of NF-jB promoter was measured by a dual-luciferase reporter assay. (D) After transfected with negative control siRNA or NLRP6 specific siRNA for 24 h, RA-FLS were transfected with NF-jB reporter plasmid and phRL-TK plasmid (internal control) for another 24 h, followed by the stimulation with TNF-a for 16 h, and the activation of NF-jB promoter was measured by a dual-luciferase reporter assay. **P < 0.01. Data are representative of three independent experiments with similar results (mean AE SD). siNC, siRNA-NC; siNLRP6, siRNA-NLRP6.
NLRP6 in RA-FLS. This research may extend our understanding of the function of NLRP6.
Rheumatoid arthritis is a chronic autoimmune disease characterized by progressive joint inflammation and hyperplasia of the synovial tissue, leading to cartilage and bone destruction [1] . It affects almost 1% of the global population and has a serious impact on the health and life of individuals. Therefore it is of great significance to explore the pathogenesis of RA and search for appropriate drug targets.
An increasing number of studies have shown that the pathologic remodeling of the cartilage, tendons and bone associated with the RA process can mainly be ascribed to the effects mediated by FLS [2, 20] . Some studies have reported that many pro-inflammatory cytokines and chemokines and growth factors could activate local RA-FLS to produce mediators such as TNF-a, IL-6, IL-1b and MMPs. This process can perpetuate synovitis, recruit new cells to the joint, destruct the extracellular matrix, and finally contribute to erosion of the bone. Therefore, molecular insights into FLS biology and related signaling pathways are required to identify the therapeutic targets. It has also been reported that extracellular heat shock protein 70 inhibits TNF-a-induced pro-inflammatory mediator production in FLS [21] . Smac127 has been reported to have proapoptotic and anti-Inflammatory effects on RA-FLS [8] . Similarly, in the present study, we found that NLRP6 is a negative regulator of inflammation in RA-FLS in that it suppressed the production of pro-inflammatory cytokines and MMPs, mainly by controlling the activation of NFjB signaling. Nucleotide oligomerization domain-like receptor are intracellular sensors that comprise a large receptor family of more than 20 members, and almost half of the NLRs have not been characterized in any detail. NLRP6 is one of the most well studied NLRs in intestinal disease. NLRP6, caspase-1 and ASC are assembled to form a molecular platform that is referred to as the NLRP6-coupled inflammasome; in this inflammasome-dependent manner, NLRP6 could protect against intestinal homeostasis by maintaining the gut microbiota composition and IL-18 production [8] . In addition, NLRP6 was found to inhibit canonical NF-jB and mitogen-activated protein kinase signaling in an inflammasome-independent manner. Deficiency in NLRP6 results in an enhanced secretion of cytokines and chemokines, although the precise mechanisms remain unknown [22] . In the present study, we also highlighted the inhibitory function of NLRP6 in the canonical NF-jB pathway in RA-FLS, which appeared in an inflammasome-independent manner. Overexpression of NLRP6 significantly inhibited the activation of NF-jB and the production of inflammatory cytokines, which is consistent with the results after NLRP6 expression was knocked down by siRNA. We also found the expression of TAB2/3 was obviously decreased in NLRP6 overexpressed RA-FLS, and the degradation is dependent on lysosome. However, the expression of TAK1 and TRAF2 was not affected by the overexpression of NLRP6.
TAB2 and TAB3 are pivotal for the activation of NF-jB pathway as binding proteins of TAK1 [22, 23] .
It has been reported that RBCK1 could negatively regulate TNF-a and that IL-1-triggered NF-jB activation by targeting TAB2/3 for proteasome-dependent degradation [24] . RNF4 was also found to negatively regulate NF-jB signaling by down-regulating TAB2 via lysosomes [25] . In addition, TRIM38 was shown to negatively regulate NF-jB activation by targeting TAB2 and TAB3 for lysosome-dependent degradation [15] . The present study aimed to investigate how NLRP6 induced the lysosome-dependent degradation of TAB2/3 by examining the interaction between NLRP6 and RNF4 or TRIM38. As shown in Fig. 6 , NLRP6 could interact with TRIM38 in a dose-dependent manner, and this interaction was greatly enhanced in the presence of TNF-a. These results indicate that, after TNF-a stimulation, NLRP6 may play a role in providing the docking site to facilitate the interaction between TAB2/3 and TRIM38 in RA-FLS, leading to TRIM38-induced lysosome-dependent degradation of TAB2/3.
In summary, we propose that, as a result of the low expression of NLRP6 in RA-FLS, the interaction between TRIM38 and TAB2/3 was weakened; therefore, excess expression of TAB2/3 leads to the continuous activation of NF-jB and the production of proinflammatory cytokines and MMPs, which finally leads to the inflammation in synovial tissues. However, the precise mechanism underlying the reduction in NLRP6 expression in RA-FLS after TNF-a stimulation requires further study.
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